Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: NAMPT

Summary for NAMPT

Gene information	Gene symbol	NAMPT
	Ensembl ID	ENSG00000105835
	Entrez ID	10135
	Gene name	nicotinamide phosphoribosyltransferase
	Synonyms	PBEF\|PBEF1
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: NAMPT

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.506754	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.360765	2.81e-13
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	0.270877	8.65e-24
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	0.298465	2.75e-13
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.288144	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.526805	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.396021	1.74e-17
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.462681	2.53e-02
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.614233	1.25e-05
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	0.319714	2.78e-41
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	-0.367076	1.33e-13
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.662645	3.24e-14
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-0.288023	6.30e-06
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	0.532201	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Mono/Macro	0.398927	5.08e-18
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	0.364582	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	-0.278926	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	-0.284727	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-0.606759	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.256395	4.25e-27
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-2.42943	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.307526	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.290617	0.00e+00
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.272301	7.11e-14
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	0.46475	5.54e-23
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.364636	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Mono/Macro	-0.474869	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	0.39684	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	0.328744	9.60e-24

Top

Expression of NAMPT in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to NAMPT

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating NAMPT

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
NAMPT	hsa-let-7c-3p	99.3565	NM_005746
NAMPT	hsa-miR-3163	99.0398	NM_005746
NAMPT	hsa-miR-4799-5p	99.0145	NM_005746
NAMPT	hsa-miR-548c-3p	98.612	NM_005746
NAMPT	hsa-miR-4282	98.442	NM_005746
NAMPT	hsa-miR-3658	98.3929	NM_005746
NAMPT	hsa-miR-4775	97.9408	NM_005746
NAMPT	hsa-miR-3611	97.8172	NM_005746
NAMPT	hsa-miR-5011-5p	96.8343	NM_005746
NAMPT	hsa-miR-513b-3p	96.7972	NM_005746
NAMPT	hsa-miR-190a-3p	96.6005	NM_005746
NAMPT	hsa-miR-5010-3p	95.9549	NM_005746
NAMPT	hsa-miR-181a-2-3p	95.6571	NM_005746
NAMPT	hsa-miR-3924	95.5556	NM_005746
NAMPT	hsa-miR-548b-3p	95.4915	NM_005746
NAMPT	hsa-miR-12136	95.3638	NM_005746
NAMPT	hsa-miR-4716-5p	94.8952	NM_005746
NAMPT	hsa-miR-301a-5p	94.7192	NM_005746
NAMPT	hsa-miR-301b-5p	94.7192	NM_005746
NAMPT	hsa-miR-4666a-5p	94.3871	NM_005746
NAMPT	hsa-miR-576-5p	94.2641	NM_005746
NAMPT	hsa-miR-590-3p	93.6477	NM_005746
NAMPT	hsa-miR-548an	93.2678	NM_005746
NAMPT	hsa-miR-8485	92.6022	NM_005746
NAMPT	hsa-miR-5696	92.0793	NM_005746
NAMPT	hsa-miR-7854-3p	91.9299	NM_005746
NAMPT	hsa-miR-6134	91.9299	NM_005746
NAMPT	hsa-miR-3978	91.6333	NM_005746
NAMPT	hsa-miR-589-3p	91.3315	NM_005746
NAMPT	hsa-miR-6757-3p	91.0587	NM_005746
NAMPT	hsa-miR-4470	90.444	NM_005746
NAMPT	hsa-miR-6841-5p	90.1966	NM_005746
NAMPT	hsa-miR-494-3p	90.145	NM_005746
NAMPT	hsa-miR-3119	89.9243	NM_005746
NAMPT	hsa-miR-4735-5p	88.7939	NM_005746
NAMPT	hsa-miR-3668	88.4872	NM_005746
NAMPT	hsa-miR-6719-3p	88.0845	NM_005746
NAMPT	hsa-miR-151a-3p	87.5472	NM_005746
NAMPT	hsa-let-7a-2-3p	87.3898	NM_005746
NAMPT	hsa-miR-1283	87.2253	NM_005746
NAMPT	hsa-miR-30c-1-3p	87.1032	NM_005746
NAMPT	hsa-miR-30c-2-3p	87.1032	NM_005746
NAMPT	hsa-miR-6788-5p	87.1032	NM_005746
NAMPT	hsa-miR-3912-5p	86.6917	NM_005746
NAMPT	hsa-miR-6878-5p	86.4005	NM_005746
NAMPT	hsa-miR-410-3p	86.3741	NM_005746
NAMPT	hsa-miR-4528	86.2723	NM_005746
NAMPT	hsa-miR-875-3p	86.0738	NM_005746
NAMPT	hsa-let-7g-3p	85.7281	NM_005746
NAMPT	hsa-miR-219b-5p	85.4004	NM_005746

Page: 1 2

Top

Motifs and transcription factors (TFs) regulating NAMPT

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
NAMPT	metacluster_161.62	HOXC8 (directAnnotation).
NAMPT	metacluster_161.64	HOXD8 (directAnnotation).
NAMPT	metacluster_161.54	HOXA5 (directAnnotation).
NAMPT	metacluster_172.22	E4F1 (inferredBy_Orthology).
NAMPT	taipale_tf_pairs__TEAD4_PITX1_RCATWCYNNNNTAATCC_CAP_repr	PITX1; TEAD4 (directAnnotation).
NAMPT	transfac_pro__M04955	ZBTB33 (directAnnotation).
NAMPT	tfdimers__MD00342	IRF1; YY1 (directAnnotation).
NAMPT	transfac_pro__M01239	RELA (directAnnotation).
NAMPT	transfac_pro__M07981	ATF3 (inferredBy_Orthology).
NAMPT	swissregulon__hs__CEBPB	CEBPB (directAnnotation).
NAMPT	tfdimers__MD00449	REL; YY1 (directAnnotation).
NAMPT	metacluster_55.3	E2F6; EGR1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; ZBTB2; ZSCAN10 (directAnnotation). NFE2L1; NRF1; NRF1; NRF1 (inferredBy_Orthology).
NAMPT	taipale_cyt_meth__ZNF385D_NCGTCGCGACGN_eDBD_meth	ZNF385D (directAnnotation).
NAMPT	taipale_tf_pairs__TFAP2C_MAX_TNSCCNNNGGSNNNNCACGTGN_CAP_repr	MAX; TFAP2C (directAnnotation).
NAMPT	transfac_pro__M00652	NRF1 (directAnnotation).
NAMPT	transfac_pro__M01298	MECP2 (directAnnotation).
NAMPT	cisbp__M00788	ZFY (inferredBy_Orthology).
NAMPT	hdpi__HIP2	UBE2K (directAnnotation).
NAMPT	transfac_pro__M02913	SP140 (inferredBy_Orthology).
NAMPT	taipale_cyt_meth__ZNF460_NRMCGCCCCCCGN_eDBD_meth	ZNF460 (directAnnotation).
NAMPT	kznf__ZNF100_Imbeault2017_RP_RCADE	ZNF100 (directAnnotation).
NAMPT	transfac_pro__M01219	SP1 (directAnnotation). SP3 (inferredBy_Orthology).
NAMPT	transfac_pro__M02898	SMAD3 (directAnnotation).
NAMPT	metacluster_151.1	KAT7; PML; SMAD5; TAF1; ZFP37; ZGPAT; ZNF519; ZNF519; ZNF571; ZNF770; ZNF770; ZNF770; ZSCAN22; ZSCAN22 (directAnnotation).
NAMPT	metacluster_191.5	SPDEF (inferredBy_Orthology).
NAMPT	taipale_tf_pairs__TFAP2C_E2F8_NNTCCCGCNNNCCNNNGGC_CAP_repr	E2F8; TFAP2C (directAnnotation).
NAMPT	hdpi__TIMELESS	TIMELESS (directAnnotation).
NAMPT	transfac_pro__M04893	TAF1 (directAnnotation).
NAMPT	cisbp__M00249	WT1 (directAnnotation).
NAMPT	transfac_pro__M00430	E2F1 (directAnnotation).
NAMPT	transfac_pro__M01090	SMAD9 (inferredBy_Orthology).
NAMPT	hdpi__ZNF304	ZNF304 (directAnnotation).
NAMPT	metacluster_66.4	ARNT2; NR0B1; NR0B1; ZSCAN5A; ZSCAN5A (directAnnotation). ARNT2 (inferredBy_Orthology).
NAMPT	transfac_pro__M00938	E2F1 (directAnnotation).
NAMPT	kznf__ZNF571_Imbeault2017_OM_RCADE	ZNF571 (directAnnotation).
NAMPT	metacluster_144.8	ZNF30; ZNF30 (directAnnotation).
NAMPT	metacluster_141.5	NR3C1; THAP1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY2; YY2; ZNF597 (directAnnotation). YY1; YY1; YY1; YY2; ZFP42 (inferredBy_Orthology).
NAMPT	kznf__ZFP57_Imbeault2017_RP_ChIP-seq	ZFP57 (directAnnotation).
NAMPT	jaspar__MA1721.1	ZNF93 (directAnnotation).
NAMPT	kznf__ZNF548_Imbeault2017_RP_RCADE	ZNF548 (directAnnotation).
NAMPT	dbtfbs__ZBTB8A_HEK293_ENCSR481FEC_merged_N1	ZBTB8A (directAnnotation).
NAMPT	transfac_pro__M01199	TRIM28 (directAnnotation).
NAMPT	metacluster_133.1	ZNF304; ZNF304; ZSCAN22 (directAnnotation).
NAMPT	dbtfbs__ZSCAN30_HEK293_ENCSR768VNZ_merged_N1	ZSCAN30 (directAnnotation).
NAMPT	taipale_tf_pairs__ETV5_HES7_CCGGAANNNNNNCACGTG_CAP	ETV5; HES7 (directAnnotation).
NAMPT	transfac_pro__M01253	CNOT3 (directAnnotation).
NAMPT	flyfactorsurvey__Mad_FlyReg_FBgn0011648	SMAD9 (inferredBy_Orthology).
NAMPT	dbtfbs__ZNF407_representative_N1	ZNF407 (directAnnotation).
NAMPT	metacluster_144.5	ZNF610; ZNF610; ZNF610 (directAnnotation).
NAMPT	taipale_cyt_meth__ZBTB37_NYACCGCRNNYACCGYR_eDBD_meth_repr	ZBTB37 (directAnnotation).

Page: 1 2 3 4 5 6

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
NAMPT	"CHS-828"	DB12980	small molecule
NAMPT	"Daporinad"	DB12731	small molecule
NAMPT	"GMX1777"	DB05217	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."